Double-Punch treatment tested for Tough-to-Treat blood cancer
NCT ID NCT06768905
Summary
This study is testing a two-step treatment for adults with an aggressive type of lymphoma (DLBCL) that has returned or not responded to prior chemotherapy. First, patients receive a single dose of a targeted radiation drug. Then, they receive an approved CAR-T cell therapy, which uses the patient's own modified immune cells to fight the cancer. The main goals are to see if this combination is safe and if it can eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.